Summary & Overview
CPT 0096U: Male Urine High-Risk HPV PCR Assay
CPT code 0096U designates a Proprietary Laboratory Analyses (PLA) test: a Roche Cobas® automated PCR assay performed by Molecular Testing Labs for detection of 14 high–risk HPV genotypes from a male urine specimen. As a PLA code, 0096U identifies a single manufacturer- or lab-specific diagnostic service, which matters for coverage, coding clarity, and tracking of utilization for this specific test nationally. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. This publication provides an executive overview of the code’s clinical context, the service setting, and the implications of PLA designation for billing and payer engagement. Readers will find concise benchmarks on payer coverage patterns where available, summaries of relevant policy considerations for proprietary assays, and clinical context on use of urine-based high–risk HPV testing in males. Data not available in the input is noted where applicable. The content is intended to inform coding teams, laboratory billing staff, and policy analysts about the identification, classification, and typical service delivery setting for CPT code 0096U without providing clinical recommendations.
Billing Code Overview
CPT code 0096U is a Proprietary Laboratory Analyses (PLA) code for a specific high–risk human papillomavirus (HPV) test performed by Molecular Testing Labs using the Roche Cobas® automated PCR platform. The code applies exclusively to the single, manufacturer- or lab-specific assay that detects 14 high–risk HPV genotypes in a male urine specimen.
-
Service type: Laboratory molecular diagnostic test (automated PCR high–risk HPV assay)
-
Typical site of service: Clinical laboratory or reference laboratory processing urine specimens
Clinical & Coding Specifications
Clinical Context
A 28-year-old male presents to an outpatient urology or sexual health clinic requesting noninvasive screening for high‑risk human papillomavirus (HPV) after a partner has a recent abnormal cervical screening. A midstream urine specimen is collected in the clinic and sent to Molecular Testing Labs for analysis using the Roche Cobas® automated PCR platform. The test is a Proprietary Laboratory Analyses code reported as 0096U and identifies 14 high‑risk HPV genotypes. Typical workflow: order placed in the electronic health record, patient voids into a sterile container per collection instructions, specimen labeled and transported to the clinic laboratory or couriered to the reference lab, accessioning, automated PCR processing on the Roche Cobas® system, results routed back to the ordering clinician. Results are used for sexual health counseling, risk assessment, and possible referral for further evaluation if positive (for example, visual inspection or specialty referral). Typical site of service: outpatient clinic, ambulatory care center, or reference laboratory performing the test.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default reporting | Use when no special circumstances or modifiers apply. |
11 | Professional component | Use when reporting only the professional component of a test if the laboratory has split billing for professional interpretation separate from technical processing. |
26 | Professional component | Use when the physician or qualified professional billed separately for interpretation of the test result. |
52 | Reduced services | Use when testing was partially performed or a reduced service occurred (rare for automated PLA tests). |
53 | Discontinued procedure | Use if specimen collection or testing was begun but discontinued for extenuating circumstances. |
59 | Data not available in the input. | Data not available in the input. |
62 | Two surgeons | Use only if two practitioners of different specialties both bill for distinct services related to specimen collection or processing (rare for this test). |
78 | Unplanned return to OR | Use only if an unplanned return to the operating room led to additional related testing (unlikely for this outpatient urine test). |
80 | Assistant surgeon | Use when an assistant surgeon participates in a procedure that triggered ancillary testing (unlikely for this test). |
AD | Advanced diagnostic laboratory test | Use when payer-specific rules require this modifier for advanced diagnostics (payer-specific guidance applies). |
QX | Ordering/servicing physician attests to CLIA compliance | Use when the ordering or performing provider needs to assert the supervising laboratory personnel met CLIA requirements. |
QY | Ordering/servicing physician not reporting technical component | Use when the performing lab bills the technical component and the ordering physician bills separately (laboratory and clinician split billing situations). |
TC | Technical component | Use when reporting only the technical component of the test (instrumentation, reagent, and processing) by the performing laboratory. |
SH | Senior Health Practitioner | Use when a senior practitioner performed the professional component under applicable payer rules. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
103K00000X | Diagnostic Laboratory | Facilities and labs that perform molecular diagnostics, including Roche Cobas® PCR testing. |
2080P0208X | Urology | Urologists who may collect urine specimens and order high‑risk HPV testing in male patients. |
261QM0800X | Infectious Disease | Specialists who may order and interpret high‑risk HPV molecular testing for clinical management. |
207Q00000X | Obstetrics & Gynecology | Clinicians coordinating partner management and sexual health screening discussions. |
208D00000X | Family Medicine | Primary care clinicians who order screening tests and counsel patients on results. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
Z11.3 | Encounter for screening for infections with a predominantly sexual mode of transmission | Common reason for ordering high‑risk HPV screening in asymptomatic individuals or partner management. |
Z20.2 | Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission | Use when a patient reports recent exposure to a partner with HPV or abnormal cervical screening. |
A63.0 | Anogenital (venereal) warts | Related sexual health diagnosis prompting evaluation for HPV, including high‑risk types for oncogenic risk assessment. |
R92.8 | Other abnormal and inconclusive findings on diagnostic imaging of breast (use cautiously for abnormal screening workflows) | Data not directly applicable but may appear in broader screening contexts; include only when clinically relevant. |
D07.9 | Carcinoma in situ of skin, unspecified | Represents premalignant conditions in anogenital region where HPV testing may be part of evaluation. |
C51.9 | Malignant neoplasm of vulva, unspecified | Included for partner management contexts and when high‑risk HPV testing informs oncologic risk evaluation. |
C53.9 | Malignant neoplasm of cervix uteri, unspecified | Relevant in partner screening scenarios where a partner has cervical cancer or high‑grade lesions prompting testing. |
R87.619 | Unspecified abnormal cytology of cervix (Pap smear) | Relevant when partner abnormal cytology leads to screening of the male partner. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
87491 | Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high‑risk types, direct probe technique, 1–5 types, qualitative | Alternative molecular HPV test sometimes used instead of the specific PLA 0096U when not using a proprietary assay; used in workflows when non‑proprietary codes apply. |
87623 | Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), types 16 and 18 and high‑risk types, multiplex reverse transcription or amplification, each type, direct probe technique, includes typing | Another commonly billed HPV molecular assay that may be ordered for broader genotyping in male patients; may be performed when lab does not use the Roche Cobas® proprietary assay. |
99000 | Handling and/or conveyance of specimens for transfer from the office to a laboratory | Ancillary code used for specimen handling and shipping when the clinic bills for specimen transport associated with sending urine to a reference lab. |
G0476 | Clinical Laboratory Improvement Amendments (CLIA) waived test (not otherwise classified) | May apply in payer-specific reporting contexts for waived or point-of-care molecular tests; listed here as a related laboratory billing consideration. |
0001U | Proprietary Laboratory Analyses (example PLA) | Other PLA codes may be billed for different proprietary HPV assays; listed to indicate that 0096U belongs to the PLA family of codes. |